ASCEND-4

一行要約

未治療 ALK 陽性 NSCLC 1L における 2nd-gen Ceritinib vs プラチナ/Pemetrexed 化学療法の phase III。PFS HR 0.55 (16.6 vs 8.1 mo) で有意に PFS を延長し、2nd-gen ALK-TKI の 1L option としての有効性を確立。ただし CNS penetration と忍容性で Alectinib (ALEX) との差が議論となった。

試験デザイン

• 対象: Stage IIIB/IV ALK 陽性 NSCLC (VENTANA IHC or FISH)、未治療 (脳転移は安定・治療済みなら許容)、ECOG PS 0-2、N=376 (1:1)
• 介入群 (n=189) : Ceritinib 750 mg/day (空腹時服用)
• 対照群 (n=187) : Platinum (Cisplatin or Carboplatin) + Pemetrexed Q3W × 4 cycles → Pemetrexed maintenance
• 層別化: 脳転移有無、WHO PS (0 vs 1-2)
• 主要評価項目: PFS (BIRC 判定)

主要結果

• PFS (primary) : HR 0.55 (95% CI 0.42–0.73, p<0.00001)、median 16.6 vs 8.1 mo
• ORR: 73% vs 27%
• Intracranial response: 脳転移あり群で intracranial ORR 73% (Ceritinib) vs 27% (化療)、intracranial PFS HR 0.40
• OS: 未成熟 (interim HR 0.73、p=0.056)。crossover と長い post-PD survival の影響
• Grade ≥3 AE: Ceritinib 65% vs 化療 49%。Ceritinib で下痢 5%、ALT 上昇 31%、GGT 上昇 24% — 肝毒性が顕著
• 用量調整: 750 mg 空腹時で GI toxicity が高頻度。後に 450 mg 食後服用 (ASCEND-8 study で bioequivalence 確認) が推奨

臨床的意義

• 2nd-gen ALK-TKI 1L の確立: PROFILE-1014 (Crizotinib vs chemo) で確立された ALK-TKI 1L を次世代薬に更新。ALEX (Alectinib vs Crizotinib)、J-ALEX と並行して 2nd-gen ALK-TKI 1L 標準化を推進
• Ceritinib vs Alectinib の間接比較: PFS は類似 (ASCEND-4: 16.6 mo vs ALEX: 25.7 mo) だが、Alectinib は CNS penetration と忍容性で優位。結果として多くの地域で Alectinib が preferred 1L に
• 用量最適化の教訓: 750 mg 空腹時投与の toxicity 問題は ALK-TKI 開発における「用量最適化」の重要性を示し、ASCEND-8 (450 mg 食後) へ繋がった
• 後続世代への文脈: CROWN (Lorlatinib 1L) が PFS HR 0.27 を示し、ALK 1L は 3rd-gen 時代へ移行

Open Questions

• Ceritinib の残存 niche: Alectinib / Lorlatinib 1L が主流化した中で Ceritinib の使用場面 (cost / access 問題で一部地域では依然 relevant)
• ALK 1L sequential strategy: Ceritinib 1L → Lorlatinib 2L vs Alectinib 1L → Lorlatinib 2L の OS comparison
• Ceritinib 耐性パターン: 1L Ceritinib 後の resistance mutation spectrum と次治療選択

重要論文 Top 10

1. ★★★★★ Soria et al. Lancet 2017 — Primary publication — PFS HR 0.55、Ceritinib 1L
2. ★★★★ Cho et al. JThoracOncol 2019 (ASCEND-8) — 450 mg 食後の bioequivalence — 用量最適化
3. ★★★★★ Peters et al. NEnglJMed 2017 (ALEX) — Alectinib 1L — ASCEND-4 との間接比較文脈
4. ★★★★★ Solomon et al. NEnglJMed 2014 (PROFILE-1014) — Crizotinib 1L — ALK-TKI 1L 標準の元祖
5. ★★★★★ Shaw et al. NEnglJMed 2020 (CROWN) — Lorlatinib 1L — 3rd-gen へ世代交代

関連エンティティ・概念

• 薬剤: Ceritinib / Platinum-chemotherapy / Pemetrexed
• 関連試験: ALEX (Alectinib 1L) / J-ALEX (日本 Alectinib 1L) / PROFILE-1014 (Crizotinib 1L) / CROWN (Lorlatinib 1L) / ALTA-1L (Brigatinib 1L)
• 関連遺伝子: ALK
• ドメイン: lung-cancer-treatment

関連論文

Basic-Brain metastasis

• Page et al. EurJCancer 2020 — Systemic treatment of brain metastases in non-small cell lung cancer

Clinical-NSCLC-ALK

• Lovly et al. AmSocClinOncolEducBook 2017 — Managing resistance to EFGR-and ALK-targeted therapies
• Katayama et al. CancerSci 2018 — Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer
• Gainor et al. ClinCancerRes 2015 — Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib
• Cadranel et al. ERJOpenRes 2018 — Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients
• Solomon et al. JClinOncol 2018 — Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in
• Shaw et al. JClinOncol 2019 — ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung
• Camidge et al. JClinOncol 2020 — Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer second interim
• Cho et al. JThoracOncol 2017 — ASCEND-8 A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted
• Cho et al. JThoracOncol 2019 — Efficacy and safety of ceritinib (450 mgd or 600 mgd) with food versus 750-mgd fasted in patients with ALK receptor
• Lin et al. JThoracOncol 2020 — Efficacy of PlatinumPemetrexed combination chemotherapy in ALK-positive NSCLC refractory to second-generation ALK
• Nishio et al. JThoracOncol 2020 — Final overall survival and other efficacy and safety results from ASCEND-3 phase II study of ceritinib in ALKi-naive
• Soria et al. Lancet 2017 — First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer
• Kim et al. LancetOncol 2016 — Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1) updated results
• Califano et al. LungCancer 2017 — Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer
• Camidge et al. NEnglJMed 2018 — Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
• Kaneda et al. SciRep 2020 — Ceritinib in japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer interim analysis

Clinical-NSCLC-ROS1

• Solomon et al. LancetOncol 2018 — Lorlatinib in patients with ALK-positive non-small-cell lung cancer results from a global phase 2 study